Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Treat Patients
Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary…
May 2, 2019 - 2 minutes
Genkyotex
Solid Phase II Performance for French Autoimmune Liver Disease Drug
Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease…
November 7, 2018 - 2 minutes
This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis
Genkyotex has announced a new Phase II trial in diabetic kidney disease and patient enrolment…
June 29, 2017 - 2 minutes
In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United…
May 30, 2017 - 7 minutes
French Biotech gets a Second Opportunity to Fight Liver Fibrosis
Genkyotex, a French biotech with an eye on NASH, has received FDA approval to initiate…
May 3, 2017 - 3 minutes
Not to be Underestimated: What’s the Hype around NASH?
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of…
February 7, 2017 - 10 minutes
Infographic: The Anatomy of European Biotech
Which part of our body do European biotechs prefer to target? And how diversified are…
December 10, 2015 - 1 minute
Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II
The French biotech Genkyotex has announced Phase II results for GKT137831 in diabetic kidney disease.…
September 10, 2015 - 2 minutes
